Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Puma Biotechnology reports revenue growth and strategic advancements in oncology

Puma Biotechnology's Q4 2022 performance reflects revenue growth, cost reductions, and a focus on improving NERLYNX sales.
The company faces challenges in addressing financial losses, FDA trial requirements, and optimizing commercial strategies.
Opportunities in advancing clinical programs, FDA discussions, and market expansion present avenues for future growth and innovation.
Overall, Puma's strategic focus on revenue enhancement, cost control, and innovative treatments positions them for continued progress in the oncology market.

Puma Biotechnology reports solid Q1 earnings, eyes oncology expansion

Puma Biotechnology's Q1 2023 performance driven by strong NERLYNX sales and revenue growth.
Focus on in-licensing alisertib and optimizing expenses for sustained profitability.
Challenges include competition, patent issues, and trial enrollment hurdles.
Opportunities lie in expanding alisertib's indications and in-licensing assets for growth.

Puma Biotechnology reports revenue growth and advances in clinical trials

Puma Biotechnology's Q2 2023 performance showcased revenue growth driven by NERLYNX sales and promising results from alisertib trials. Despite challenges in NERLYNX prescriptions and FDA expectations, strategic initiatives aim to boost sales and advance clinical development. Opportunities in commercial strategies and clinical trials present avenues for future growth.

Puma Biotechnology reports solid Q3 earnings amidst sales challenges

Puma Biotechnology reported solid financial performance in Q3 2023 despite challenges in NERLYNX sales.
The company's focus on improving sales, pursuing clinical trials, and reducing expenses positions it for future growth.
Opportunities lie in enhancing NERLYNX sales, diversifying the product portfolio, and achieving clinical milestones.
Navigating challenges in sales and portfolio diversification while capitalizing on opportunities will be key for Puma's success.

Puma Biotechnology reports stable Q4 earnings amidst prescription challenges

Puma Biotechnology's Q4 2023 performance reflects solid revenue figures and a focus on profitability despite prescription declines.
The company's strengths lie in its innovative trials, commercial strategies, and optimistic revenue projections for the future.
Challenges include prescription decreases and inventory impacts, while opportunities exist in diversification, engagement enhancement, and market differentiation.

Puma Biotechnology reports revenue growth and strategic expansion plans

Puma Biotechnology's Q1 2024 performance reflects revenue growth and strategic initiatives to drive sales and enhance profitability.
While facing challenges in maintaining NERLYNX sales and managing expenses, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, financial stability, and market expansion, Puma is poised for continued growth and success in the biotechnology sector.
Investors should monitor Puma's progress in clinical trials, revenue diversification, and cost management for insights into its future performance.

Puma Biotechnology reports strong revenue, eyes product approvals for growth

Puma Biotechnology's Q2 2024 performance reflects solid revenue generation and strategic investment in innovation.
While facing challenges such as declining new prescriptions and a net loss, the company maintains a focus on cost management.
Opportunities lie in product approvals, revenue growth, and leveraging financial stability for future growth initiatives.
Overall, Puma's financial outlook remains positive, supported by a strong product pipeline and prudent financial management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented final overall survival analysis from its Phase III ExteNET Trial at the 2020 San Antonio Breast Cancer Symposium.

Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented updated results from its Phase II SUMMIT trial in a Spotlight Poster at the 2020 San Antonio Breast Cancer Symposium.

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock?

Why Is Puma Biotech (PBYI) Up 36% Since Last Earnings Report?

LOS ANGELES--(BUSINESS WIRE)--European Patent Office Upholds Puma Biotechnology's Patent Position on EP 1848414 as Granted.

Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted

Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.

Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut

Puma Biotechnology's (PBYI) CEO Alan Auerbach on Q3 2020 Results - Earnings Call Transcript

Puma Biotech (PBYI) delivered earnings and revenue surprises of -139.39% and -4.17%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Puma Biotech (PBYI) Reports Q3 Loss, Lags Revenue Estimates

LOS ANGELES--(BUSINESS WIRE)--On Nov. 5, 2020, Puma Biotechnology released interim results from its Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 mutated, metastatic NSCLC.

Puma Biotechnology Announces Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer

LOS ANGELES--(BUSINESS WIRE)--On Nov. 5, 2020, Puma Biotechnology reported its financial results for the third quarter and nine months ended Sept. 30, 2020.

Puma Biotechnology Reports Third Quarter 2020 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will provide a corporate update at the Credit Suisse Virtual Healthcare Conference on Nov. 10

Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference

PLYMOUTH MEETING, Pa., Oct. 15, 2020 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced plans to evaluate neratinib, a type of tyrosine kinase inhibitor (TKI) that works as a dual inhibitor of the epidermal growth factor...

NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers

LOS ANGELES--(BUSINESS WIRE)--Overall survival results from Puma Biotechnology's Phase III ExteNET trial were published online in Clinical Breast Cancer.

Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET Trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer

SAN DIEGO--(BUSINESS WIRE)--On September 8, 2020, a Court-appointed administrator confirmed the claims of more than 4,600 individual and institutional investors defrauded by Puma Biotechnology and its CEO, Alan Auerbach. The total damages these investors will recover, including pre- and post-judgment interest, exceed $55 million.

Robbins Geller Rudman & Dowd LLP Announces Jury Verdict Finding Puma Biotechnology and CEO Alan Auerbach Committed Securities Fraud Results in Damages Three to Six Times Higher Than the Company Claimed

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO Alan Auerbach will provide a  company overview at the virtual H.C. Wainwright Global Conference on September 15, 2020.

Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Why Is Puma Biotech (PBYI) Down 7.2% Since Last Earnings Report?

LOS ANGELES--(BUSINESS WIRE)--A manuscript including results from Puma Biotechnology's CONTROL trial was published in the September 2020 issue of Annals of Oncology.

Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology

Puma Bio: A Contrarian Investment That Requires Patience

Puma Biotech's (PBYI) bottom and the top line better estimates for the second quarter of 2020.

Puma's (PBYI) Earnings and Revenues Beat Estimates in Q2

Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q2 2020 Results - Earnings Call Transcript

Shares of Puma Biotechnology (NASDAQ:PBYI) rose 0.32 in after-market trading after the company reported Q2 results.

Recap: Puma Biotechnology Q2 Earnings

LOS ANGELES--(BUSINESS WIRE)--On Aug. 6, 2020, Puma Biotechnology released its financial results for the third quarter and six months ended June 30, 2020.

Puma Biotechnology Reports Second Quarter 2020 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology's P 2  SUMMIT trial results of neratinib in HER2-Mutant, metastatic cervical cancers were published online in Gynecologic Oncology.

Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers

IRVING, Texas--(BUSINESS WIRE)--Acentrus Specialty finalizes an agreement with Puma Biotechnology, Inc. to provide qualified Acentrus clients access to NERLYNX® (neratinib).

Acentrus Specialty Partners with Puma Biotechnology to Bring Nerlynx® (neratinib) to Health Systems and Hospitals in the Acentrus Network

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology's licensing partner Specialised Therapeutics Asia received authorization to market NERLYNX in Malaysia.

Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer

Puma Biotechnology shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 86.
The post Puma Biotechnology Clears Technical Benchmark, Hitting 80-Plus RS Rating appeared first on Investor's Business Daily.

News for Puma Biotechnology Stock (PBYI)